This study evaluated the cost-effectiveness of iron treatments in anemic HD patients, demonstrating that FCM was the more effective treatment option compared to FG, reducing ESA dose requirements, increasing Hb levels, and improving iron status. Here, GSTM1 is linked to Huntington disease.